Innate Pharma SA

Innate Pharma SA (IPHYF) has logged zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in our near-term monitoring window. However, a 90-day clean sheet does not indicate absence of structural risk; the biotech sector presents ongoing dilution and financing pressures that require deeper context. The full $49 Report extends analysis to 12 months of SEC filings, adds dilution risk scoring, financing history review, and AI-detected signals that short-term snapshots miss. The full $49 Report adds quantified dilution trajectory, 8-K pattern analysis, and forward-looking risk signals across a full fiscal year.